Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of QLS1304 plus endocrine therapy in ER-positive/HER2-negative breast cancer
CTR20254691Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS1304 in breast cancer, sponsored by Qilu Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
QLS1304
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254691.